Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform
Journal
ACS Applied Materials and Interfaces
Journal Volume
13
Journal Issue
48
Pages
57036-57042
Date Issued
2021-01-01
Author(s)
Han, Hsiao Fen
Yen, Hung Chi
Wu, Hsiu Chuan
Tan, Hsin Yuan
Xu, Wei
Jiang, Hang Shiang
Tsai, Ping Jui
Qian, Kun
Chen, Chia Chun
Abstract
More than 55 million people live with dementia worldwide in 2021, and there are nearly 10 million new cases every year. Alzheimer's disease (AD) is the most common cause of dementia. Despite urgent need, early detection of AD and long-term monitoring of AD progression have been challenging. This is due to the limited availability of brain imaging facilities and the highly invasive procedure with the cerebrospinal fluid assay to assess the level of AD biomarkers, such as beta-amyloid (Aβ). Reliable measurements of AD biomarkers in blood samples are still difficult because of their very low abundance. Here, we develop a rapid, specific, and ultrasensitive immunoassay using plasmonic-gold nanoisland (pGOLD) chips with near-infrared fluorescence-enhanced detection for Aβ1-40 and Aβ1-42. We show step-by-step processes and results during the platform establishment, including antibody specificity and sensitivity tests, antibody pair examination, condition optimization, and procedure refinement. Finally, we demonstrate the platform performance with detection sensitivity at the subpicogram per milliliter level. This platform, therefore, has a great application potential for early detection of AD using blood samples.
Subjects
Alzheimer's disease | beta-amyloid | blood biomarkers | plasmonic-gold chip | surface plasmon-enhanced fluorescence
SDGs
Publisher
American Chemical Society
Type
journal article